Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2020 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer

AUSTIN, Texas, April 24, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron...
April 02, 2020 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer

AUSTIN, Texas, April 02, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the promotion of...
March 30, 2020 08:00 ET | Source: NewLink Genetics Corporation

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board

AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the...
March 18, 2020 08:00 ET | Source: NewLink Genetics Corporation; Lumos Pharma, Inc.

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren)...
February 28, 2020 09:00 ET | Source: NewLink Genetics Corporation

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

AMES, Iowa, Feb. 28, 2020 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided...
December 23, 2019 16:05 ET | Source: NewLink Genetics Corporation

NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207

AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses...
December 20, 2019 10:09 ET | Source: NewLink Genetics Corporation

NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus...
December 16, 2019 08:00 ET | Source: NewLink Genetics Corporation

NewLink Genetics Responds to Proposal from Evercel

AMES, Iowa, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink” or the “Company”) today publicly announced its rejection of the unsolicited acquisition proposal...
November 12, 2019 09:00 ET | Source: NewLink Genetics Corporation

NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing...
November 06, 2019 08:00 ET | Source: NewLink Genetics Corporation

NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

AMES, Iowa, Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on...